Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 858 participants.

Also called NCT04437303

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 858 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04437303
Other papers using this trial's data
  • Continuation versus Interruption of Oral Anticoagulation during TAVI The New England journal of medicine, 2025-01-30 DOI, PubMed 39216096

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Denmark, Ireland, Italy, Luxembourg, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04437303. Randomized; single masking; primary purpose prevention. Start 2020-11-25 (actual); primary completion 2024-03-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)
Condition
Aortic Valve Disease
Condition
Aortic Valve Stenosis
Condition
Stroke
Condition
Bleeding
Condition
Vascular Complications
Condition
Thrombosis Embolism
Intervention (Drug)
Continuation of oral anticoagulants
Intervention (Drug)
Interruption of oral anticoagulants
Lead sponsor
St. Antonius Hospital (class: other)

Record details

Record id
cardio:ct-nct04437303
Content hash
c860bf9732ed5a2131b89b29f0bbbe6cfdfc8f3b121088a3122d771bc6a40d80